Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

p> Therapeutics Inc. - - 2,156,685

Gain on sale of BCY

LifeSciences Inc. - - (299,403)

Cancellation of contingent

payment obligation settled

in common shares - - 150,000

Future income tax recovery - - (1,115,000)

-------------------------------------------------------------------------

- - 1,383,537

-------------------------------------------------------------------------

-------------------------------------------------------------------------

6. CAPITAL DISCLOSURES

The Company's objective when managing capital is to maintain adequate

cash resources to support planned activities which include the clinical

trial program, product manufacturing, administrative costs and

intellectual property expansion and protection. The Company includes

shareholders' equity, cash and short-term investments in the definition

of capital. The Company does not have any debt other than trade accounts

payable and has potential contingent obligations relating to the

completion of its research and development of REOLYSIN(R).

In managing capital, the Company estimates its future cash requirements

by preparing a budget and a multiyear plan annually for review and

approval by the Company's board of directors (the "Board"). The budget

establishes the approved activities for the upcoming year and estimates

the costs associated with these activities. The multiyear plan estimates

future activity along with the potential cash requirements and is based

on the Company's assessment of its current clinical trial progress along

with the expected results from the coming year's activity. Budget to

actual variances are prepar
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... York (PRWEB) August 29, 2014 According to ... Orthobiologics Market” the global orthobiologics market was valued at USD ... market worth USD 5,519.9million in 2019at a CAGR of 5.9% ... aged 50 years and above is afflicted by bone and ... by the year 2020. This has and will continue to ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
(Date:8/29/2014)... Three Lawrence Livermore researchers have ... Production R&D Award for their research in ... sunlight. , Shared with collaborators from the National ... Nevada, Las Vegas (UNLV), the award recognizes the ... solar-hydrogen production and corrosion processes. , These models ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... BIG SP, Company or Biosensors), today announced that ... for its,BioMatrix(R) drug-eluting stent system, enabling commercialization of ... in Asia and Latin America,that recognize the CE ... the Company, consists of a unique drug-eluting,stent that ...
... Calif., Jan. 17 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... meetings including yearend business review, planning for ... in,Xiaotangshan, Beijing on January 11, 2008., ... from Kiwa,s corporate,headquarters in Beijing, and department ...
... formed Advisory Board to advise on cancer screening methods ... mitochondrial DNA-based disease ... (OTC,Bulletin Board: TBIO) today announced that it has formed ... latest developments and,scientific opportunities in cancer detection screening and ...
Cached Biology Technology:Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 2Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 3Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 4Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 2Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 3Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3
(Date:8/28/2014)... method for delivering compounds that could positively ... AIDS may be possible, thanks to researchers ... A semi-soft vaginal suppository made from the ... the antiviral drug Tenofovir provides a woman-initiated, ... spread of sexually transmitted infections during unprotected ...
(Date:8/28/2014)... for measuring and imaging how quickly blood flows in ... how drug abuse affects the brain, which may aid ... to better treatment options for recovering drug addicts. The ... Stony Brook University in New York, USA and the ... The Optical Society,s (OSA) open-access journal Biomedical ...
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Nanoscale assembly line 2Nanoscale assembly line 3
... has discovered that aggressive melanoma cells secrete Nodal, ... formation. , An article describing this research ... of the journal Nature Medicine. The researchers identified the ... injecting aggressive melanoma cells into developing zebrafish embryos, ...
... known more for conflict than conservation, a joint effort ... Society (WCS) and funded by the United States Agency ... the region's unique wildlife and develop the country's first ... is an important and exciting moment for Afghanistan, which ...
... Methylphenidate (Ritalin) elevates norepinephrine levels in the brains ... nerve signal transmissions in the sensory pathways to ... a Philadelphia research team has found. , Their ... how a stimulant aids people with attention deficit ...
Cached Biology News:Malignant melanoma cells secrete protein required for embryo formation 2Afghanistan to protect wildlife and wild lands 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3